| Identification | Back Directory | [Name]
2-Pyridinecarboxamide, N-[2-[trans-4-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]-7-azaspiro[3.5]non-7-yl]methyl]cyclohexyl]-6-(1-hydroxy-1-methylethyl)-2H-indazol-5-yl]-6-(trifluoromethyl)- | [CAS]
2432993-46-7 | [Synonyms]
KTX-497
2-Pyridinecarboxamide, N-[2-[trans-4-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]-7-azaspiro[3.5]non-7-yl]methyl]cyclohexyl]-6-(1-hydroxy-1-methylethyl)-2H-indazol-5-yl]-6-(trifluoromethyl)- | [Molecular Formula]
C45H49F3N8O6 | [MOL File]
2432993-46-7.mol | [Molecular Weight]
854.92 |
| Hazard Information | Back Directory | [Uses]
KTX-497 is an IRAK4 PROTAC degrader with a DC50 value of 3 nM. KTX-497 can be used for the research of oncology[1].(Pink:IRAK4 inhibitor (HY-150735); Black: linker; Blue: CRBN Ligand (HY-10984)) | [in vivo]
KTX-497 (oral; 10 mg/kg) impacts oral absorption[1]. | Animal Model: | Rat[1] | | Dosage: | 10 mg/kg | | Administration: | Oral | | Result: | Impacted oral absorption. |
| [IC 50]
IRAK4: 3 nM (DC50) | [References]
[1] Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications. |
|
|